Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel
OTCMKTS:DSNKY

Daiichi Sankyo Q3 2026 Earnings Report

Daiichi Sankyo logo
$18.67 +0.39 (+2.13%)
As of 09/25/2026 03:59 PM Eastern
ProfileEarnings HistoryForecast

Daiichi Sankyo EPS Results

Actual EPS
$0.30
Consensus EPS
$0.25
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Daiichi Sankyo Revenue Results

Actual Revenue
$3.65 billion
Expected Revenue
$3.88 billion
Beat/Miss
Missed by -$232.10 million
YoY Revenue Growth
N/A

Daiichi Sankyo Announcement Details

Quarter
Q3 2026
Date
1/29/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Daiichi Sankyo's next earnings date is estimated for Friday, October 30, 2026, based on past reporting schedules.

Conference Call Resources

Daiichi Sankyo Earnings Headlines

Merck, Daiichi Sankyo withdraw US application for lung cancer drug
September 25 at 4:38 PM  |  reuters.comhttps://www.reuters.com/legal/litigation/merck-daiichi-sankyo-withdraw-us-application-lung-cancer-drug-2026-09-25/
Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up After Analyst Upgrade
September 24 at 5:32 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044438
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.tc pixel
September 26 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Astra-Daiichi breast cancer drug Enhertu recommended for NHS use in England
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/astra-daiichi-breast-cancer-drug-enhertu-recommended-for-nhs-use-in-england/ar-AA2crf58
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk
August 28, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260828631780/en/new-daiichi-sankyo-data-underscore-the-effect-of-bempedoic-acid-in-the-real-world-management-of-dyslipidemia-and-cardiovascular-risk/
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
August 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260821102599/en/daiichi-sankyo-appoints-markus-kosch-to-lead-europe-business-as-part-of-new-commercialization-organization/
See More Daiichi Sankyo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email.

About Daiichi Sankyo

Daiichi Sankyo (OTCMKTS:DSNKY) Co., Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies. Its broader portfolio includes Lixiana, also known as Savaysa in some markets, an oral anticoagulant based on edoxaban.

Daiichi Sankyo was formed in 2005 through the merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd., two established Japanese drugmakers. The company is headquartered in Tokyo and serves markets in Japan, North America, Europe and other international regions through its global research, manufacturing and commercial operations.

View Daiichi Sankyo Profile
Earnings Tools